StockData
Enanta Pharmaceuticals Inc logo

Enanta Pharmaceuticals Inc (ENTA) stock

ENTANasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q4 FY2026, quarter ended Sep 30, 2026Last filing: 10-K on Nov 18, 2026Score 3/306% below fair value
$7.98−0.25 (-3.04%)

Close on Nov 19, 2026Market cap $232.42MP/E –Yield –

Enanta Pharmaceuticals free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Enanta Pharmaceuticals's free cash flow for the twelve months ending Sep 30, 2026 was -$42.77M. For fiscal 2026 it was -$42.77M. The highest annual figure on record is $74.34M in fiscal 2015.

Annual free cash flow

PeriodPeriod endValueChange
FY2026Sep 30, 2026-$42.77M–
FY2025Sep 30, 2025-$32.17M–
FY2024Sep 30, 2024-$96.71M–
FY2023Sep 30, 2023-$112.21M–
FY2022Sep 30, 2022-$86.91M–
FY2021Sep 30, 2021-$70.75M-1353.7%
FY2020Sep 30, 2020$5.64M-91.5%
FY2019Sep 30, 2019$66.00M+151.5%
FY2018Sep 30, 2018$26.24M-47.7%
FY2017Sep 30, 2017$50.15M+61.4%
FY2016Sep 30, 2016$31.07M-58.2%
FY2015Sep 30, 2015$74.34M+288.2%
FY2014Sep 30, 2014$19.15M+90.6%
FY2013Sep 30, 2013$10.05M-55.1%
FY2012Sep 30, 2012$22.37M-5.1%
FY2011Sep 30, 2011$23.57M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2026CQ3 2026Sep 30, 2026-$13.77M–
Q3 FY2026CQ2 2026Jun 30, 2026-$9.98M–
Q2 FY2026CQ1 2026Mar 31, 2026-$7.17M–
Q1 FY2026CQ4 2025Dec 31, 2025-$11.84M–
Q4 FY2025CQ3 2025Sep 30, 2025-$7.95M–
Q1 FY2025CQ4 2024Dec 31, 2024-$25.55M–
Q4 FY2024CQ3 2024Sep 30, 2024-$19.35M–
Q3 FY2024CQ2 2024Jun 30, 2024-$21.32M–
Q2 FY2024CQ1 2024Mar 31, 2024-$30.27M–
Q1 FY2024CQ4 2023Dec 31, 2023-$25.78M–
Q4 FY2023CQ3 2023Sep 30, 2023-$22.97M–
Q3 FY2023CQ2 2023Jun 30, 2023-$34.28M–
Q2 FY2023CQ1 2023Mar 31, 2023-$16.17M–
Q1 FY2023CQ4 2022Dec 31, 2022-$38.80M–
Q4 FY2022CQ3 2022Sep 30, 2022-$16.97M–
Q3 FY2022CQ2 2022Jun 30, 2022-$29.85M–
Q2 FY2022CQ1 2022Mar 31, 2022-$26.45M–
Q1 FY2022CQ4 2021Dec 31, 2021-$13.63M–
Q4 FY2021CQ3 2021Sep 30, 2021-$21.05M–
Q3 FY2021CQ2 2021Jun 30, 2021-$29.91M–
Q2 FY2021CQ1 2021Mar 31, 2021-$4.71M-132.9%
Q1 FY2021CQ4 2020Dec 31, 2020-$15.08M-227.0%
Q4 FY2020CQ3 2020Sep 30, 2020-$15.79M-291.4%
Q3 FY2020CQ2 2020Jun 30, 2020-$4.76M-1671.3%
Q2 FY2020CQ1 2020Mar 31, 2020$14.32M-48.1%
Q1 FY2020CQ4 2019Dec 31, 2019$11.88M-60.2%
Q4 FY2019CQ3 2019Sep 30, 2019$8.25M-70.2%
Q3 FY2019CQ2 2019Jun 30, 2019$303.00K-89.7%
Q2 FY2019CQ1 2019Mar 31, 2019$27.58M–
Q1 FY2019CQ4 2018Dec 31, 2018$29.87M+664.9%
Q4 FY2018CQ3 2018Sep 30, 2018$27.72M-51.4%
Q3 FY2018CQ2 2018Jun 30, 2018$2.95M–
Q2 FY2018CQ1 2018Mar 31, 2018-$8.33M–
Q1 FY2018CQ4 2017Dec 31, 2017$3.91M+78.1%
Q4 FY2017CQ3 2017Sep 30, 2017$57.07M–
Q3 FY2017CQ2 2017Jun 30, 2017-$5.54M–
Q2 FY2017CQ1 2017Mar 31, 2017-$3.58M–
Q1 FY2017CQ4 2016Dec 31, 2016$2.19M–
Q4 FY2016CQ3 2016Sep 30, 2016-$2.54M–

More Enanta Pharmaceuticals figures

See a number that looks wrong?